The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose
cytarabine represents an important new therapy for older or unfit patients with acute myeloid …

Acute myeloid leukaemia (AML) is a rare but severe form of human cancer that results from a
limited number of functionally cooperating genetic abnormalities leading to uncontrolled …

Acute myeloid leukemia (AML) is a molecularly heterogeneous disease. Based on
cytogenetics and FISH, AML patients are stratified into three major risk categories …

The objective was to evaluate the prognostic and predictive impact of allelic ratio and
insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene …

X chromosome aneuploidies have long been associated with human cancers, but causality
has not been established. In mammals, X chromosome inactivation (XCI) is triggered by Xist …

Acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITD)
mutation is an aggressive hematologic malignancy with a grave prognosis. To identify the …

Clonal evolution in cancer—the selection for and emergence of increasingly malignant
clones during progression and therapy, resulting in cancer metastasis and relapse—has …

Genomic studies in acute myeloid leukemias (AML) have identified mutations that drive
altered DNA methylation, including TET2 and IDH2. Here, we show that models of AML …

Acquired resistance to selective FLT3 inhibitors is an emerging clinical problem in the
treatment of FLT3-ITD+ acute myeloid leukaemia (AML). The paucity of valid pre-clinical …

Allogeneic hematopoietic cell transplantation (alloHCT) as a postremission therapy in
patients with FLT3-ITD–positive intermediate-risk acute myeloid leukemia (AML) remains …